Head to Head Survey: 111 (NASDAQ:YI) versus Biotricity (OTCMKTS:BTCY)

Biotricity (OTCMKTS:BTCY) and 111 (NASDAQ:YI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings.

Volatility & Risk

Biotricity has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, 111 has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.

Profitability

This table compares Biotricity and 111’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biotricity	-30.02%	N/A	-75.50%
111	-0.52%	N/A	-2.70%

Analyst Ratings

This is a summary of recent ratings and target prices for Biotricity and 111, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0	0	0	0	0.00
111	1	0	0	0	1.00

Valuation and Earnings

This table compares Biotricity and 111″s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$13.79 million	0.61	-$8.42 million	($0.17)	-1.76
111	$1.97 billion	0.03	-$1.42 million	($0.84)	-6.81

111 has higher revenue and earnings than Biotricity. 111 is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

3.9% of Biotricity shares are held by institutional investors. Comparatively, 21.3% of 111 shares are held by institutional investors. 10.1% of Biotricity shares are held by company insiders. Comparatively, 43.9% of 111 shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

111 beats Biotricity on 7 of the 11 factors compared between the two stocks.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

About 111

111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.